Approval · Notice of Compliance 2236 · 2001
ESTALIS SEQUI: Notice of Compliance 2236
Issued February 23, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2236
- Date
- February 23, 2001
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Therapeutic class
- Progestin-estrogen
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESTALIS SEQUI | 02243529 | Cancelled Post Market |
| ESTALIS SEQUI | 02243530 | Cancelled Post Market |
Medicinal ingredients
- ESTRADIOL 0.62 MG per PATCH
- NORETHINDRONE ACETATE 2.7 MG per PATCH
- ESTRADIOL 0.51 MG per PATCH
- NORETHINDRONE ACETATE 4.8 MG per PATCH
- ESTRADIOL 4.33 MG per PATCH